Download the free NYSE magazine iPad app

Also in
News & Trends

Data for Home Hunters
Trulia offers a comprehensive picture of your next neighborhood.
read more

A Lower-Cost Route to a Cleaner Fuel
Celanese develops an efficient way to create ethanol sans corn.
read more

The Right Sales Technique
CEB proves that challenging customers can pay off.
read more

CEB Sidebar:
Are You Up for the Challenge?

CEB’s CEO says the majority of salespeople can boost business by using Challenger sales approach.
read more

View all of the articles in News & Trends
News & Trends

Allergan

One Drug, 25 Uses

For Allergan, a single cosmetic treatment becomes a pipeline.

By Susan Caminiti

ISTOCKPHOTO

PrintPrint E-mail |

Growth From Innovation

Pyott on Allergan’s commitment to R&D

Can one medical treatment have 25 different uses? Researchers at Allergan Inc. (NYSE: AGN), the Irvine, Calif.-based pharmaceutical company that owns Botox Cosmetic, have evolved the drug into its own pipeline, says CEO David Pyott.

In the past three years, the FDA has approved Botox to treat chronic migraines, certain cases of overactive bladder, and muscle stiffness in the elbows, wrists and fingers. That’s in addition to earlier approvals for severe underarm sweating, neck muscle spasms and uncontrollable eyelid twitching. The company is at work on applications for juvenile cerebral palsy and osteoarthritis pain, among other ailments.

Pyott says Botox is the perfect illustration of how a company can find new uses for a proven technology and expand into new business channels. For instance, he says, FDA approval in 2011 to use Botox for certain cases of overactive bladder enabled Allergan to create a new business unit: Urology.

Global sales of Botox are estimated to reach $1.76 billion to $1.8 billion for 2012, nearly 30 percent of Allergan’s total revenue. With 25 uses at different stages of development, Pyott says he isn’t worried about generics muscling their way into the market as patents expire over the next decade.